KaloBios Pharma -38% AH on decision to stop asthma study

KaloBios Pharmaceuticals (KBIO) -38.7% AH after saying it will discontinue development of its KB003 treatment for severe asthma following initial data evaluation of a Phase 2 study which didn't meet its primary clinical endpoint of improvement when compared to placebo.

KBIO had targeted the severe asthma population, which represents 5%-10% of the world's total asthma population of ~300M people.

CEO David Pritchard says KBIO will refocus efforts on advancing its other treatments under development, including an oncology program and a potential treatment for cystic fibrosis.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs